Appili Therapeutics Inc. (OTCMKTS:APLIF) Short Interest Down 69.9% in April

Appili Therapeutics Inc. (OTCMKTS:APLIF) was the recipient of a significant decline in short interest in April. As of April 15th, there was short interest totalling 37,400 shares, a decline of 69.9% from the March 31st total of 124,200 shares. Based on an average trading volume of 1,614,600 shares, the short-interest ratio is currently 0.0 days.

Appili Therapeutics Trading Up 5.7 %

APLIF traded up $0.00 during trading on Friday, hitting $0.03. 87,134 shares of the stock were exchanged, compared to its average volume of 448,459. The firm has a 50 day simple moving average of $0.03 and a 200 day simple moving average of $0.02. Appili Therapeutics has a 1 year low of $0.02 and a 1 year high of $0.08.

Appili Therapeutics (OTCMKTS:APLIF) last issued its quarterly earnings data on Tuesday, February 13th. The company reported ($0.01) earnings per share for the quarter, hitting the consensus estimate of ($0.01). The company had revenue of $0.36 million for the quarter. Analysts forecast that Appili Therapeutics will post -0.04 earnings per share for the current year.

About Appili Therapeutics

Appili Therapeutics Inc, a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis.